JP2007523155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007523155A5 JP2007523155A5 JP2006553706A JP2006553706A JP2007523155A5 JP 2007523155 A5 JP2007523155 A5 JP 2007523155A5 JP 2006553706 A JP2006553706 A JP 2006553706A JP 2006553706 A JP2006553706 A JP 2006553706A JP 2007523155 A5 JP2007523155 A5 JP 2007523155A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- benzamide
- amino
- pyrrolo
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 nitro, hydroxyl Chemical group 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 8
- KKWUYHFACPLBGF-UHFFFAOYSA-N 1-amino-n-pyridin-4-yl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2C(N)CCC2=CC=1C(=O)NC1=CC=NC=C1 KKWUYHFACPLBGF-UHFFFAOYSA-N 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 6
- OTGLOKZMFREKRJ-UHFFFAOYSA-N 4-(4,5-dihydro-1h-imidazol-2-yl)-n-pyridin-4-ylbenzamide Chemical compound C=1C=C(C=2NCCN=2)C=CC=1C(=O)NC1=CC=NC=C1 OTGLOKZMFREKRJ-UHFFFAOYSA-N 0.000 claims 5
- IQNKRAWRKBNOKR-UHFFFAOYSA-N 4-piperidin-2-yl-n-(1h-pyrrolo[2,3-b]pyridin-4-yl)benzamide Chemical compound C=1C=NC=2NC=CC=2C=1NC(=O)C(C=C1)=CC=C1C1CCCCN1 IQNKRAWRKBNOKR-UHFFFAOYSA-N 0.000 claims 5
- SQQWULIZIPGEIA-UHFFFAOYSA-N 5-amino-n-(1h-pyrrolo[2,3-b]pyridin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2C(N)CCCC2=CC=1C(=O)NC1=CC=NC2=C1C=CN2 SQQWULIZIPGEIA-UHFFFAOYSA-N 0.000 claims 5
- NHUPJCHRWRHUKF-UHFFFAOYSA-N n-pyridin-4-yl-4-pyrrolidin-2-ylbenzamide Chemical compound C=1C=C(C2NCCC2)C=CC=1C(=O)NC1=CC=NC=C1 NHUPJCHRWRHUKF-UHFFFAOYSA-N 0.000 claims 5
- QEMYLDYQDFRTRT-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinolin-2-ium-6-carboxylate Chemical compound C1NCCC2=CC(C(=O)O)=CC=C21 QEMYLDYQDFRTRT-UHFFFAOYSA-N 0.000 claims 4
- ZCYGCPVXXJYQDY-UHFFFAOYSA-N 4-piperidin-2-yl-n-pyridin-4-ylbenzamide Chemical compound C=1C=C(C2NCCCC2)C=CC=1C(=O)NC1=CC=NC=C1 ZCYGCPVXXJYQDY-UHFFFAOYSA-N 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- IIVCSIFQZZMOBI-UHFFFAOYSA-N n-pyridin-4-yl-1,2,3,4-tetrahydroisoquinoline-6-carboxamide Chemical compound C=1C=C2CNCCC2=CC=1C(=O)NC1=CC=NC=C1 IIVCSIFQZZMOBI-UHFFFAOYSA-N 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- ZFBHHXHSPRMSQS-UHFFFAOYSA-N 1-amino-2,3-dihydro-1h-indene-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2C(N)CCC2=C1 ZFBHHXHSPRMSQS-UHFFFAOYSA-N 0.000 claims 2
- ZMRMIGRTPQOGOL-UHFFFAOYSA-N 1-amino-n-(1h-pyrrolo[2,3-b]pyridin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2C(N)CCC2=CC=1C(=O)NC1=CC=NC2=C1C=CN2 ZMRMIGRTPQOGOL-UHFFFAOYSA-N 0.000 claims 2
- KRAYOARFOGSKJI-UHFFFAOYSA-N 4-(1-amino-2,2-dimethylpropyl)-n-pyridin-4-ylbenzamide Chemical compound C1=CC(C(N)C(C)(C)C)=CC=C1C(=O)NC1=CC=NC=C1 KRAYOARFOGSKJI-UHFFFAOYSA-N 0.000 claims 2
- JTVBXQAYBIJXRP-UHFFFAOYSA-N 4-(1-aminoethyl)-n-(1h-pyrrolo[2,3-b]pyridin-4-yl)benzamide Chemical compound C1=CC(C(N)C)=CC=C1C(=O)NC1=CC=NC2=C1C=CN2 JTVBXQAYBIJXRP-UHFFFAOYSA-N 0.000 claims 2
- LLSFXOUAPAZFIV-UHFFFAOYSA-N 4-(1-aminoethyl)-n-pyridin-4-ylbenzamide Chemical compound C1=CC(C(N)C)=CC=C1C(=O)NC1=CC=NC=C1 LLSFXOUAPAZFIV-UHFFFAOYSA-N 0.000 claims 2
- GMDVSDXMBONTNR-UHFFFAOYSA-N 4-(aminomethyl)-2,5-dimethyl-n-pyridin-4-ylbenzamide Chemical compound C1=C(CN)C(C)=CC(C(=O)NC=2C=CN=CC=2)=C1C GMDVSDXMBONTNR-UHFFFAOYSA-N 0.000 claims 2
- RZZGLZFZZYYVCO-UHFFFAOYSA-N 4-[2-(1-aminocyclobutyl)ethyl]-n-(1h-pyrrolo[2,3-b]pyridin-4-yl)benzamide Chemical compound C=1C=C(C(=O)NC=2C=3C=CNC=3N=CC=2)C=CC=1CCC1(N)CCC1 RZZGLZFZZYYVCO-UHFFFAOYSA-N 0.000 claims 2
- BREHCBBQUGUALM-UHFFFAOYSA-N 4-[2-(1-aminocyclopentyl)ethyl]-n-(1h-pyrrolo[2,3-b]pyridin-4-yl)benzamide Chemical compound C=1C=C(C(=O)NC=2C=3C=CNC=3N=CC=2)C=CC=1CCC1(N)CCCC1 BREHCBBQUGUALM-UHFFFAOYSA-N 0.000 claims 2
- 230000003345 hyperglycaemic effect Effects 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- RCWISWVYKNLXHC-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound NC1=CC=NC2=C1C=CN2 RCWISWVYKNLXHC-UHFFFAOYSA-N 0.000 claims 1
- HVFBLNMGJWVBOH-UHFFFAOYSA-N 4-(1-amino-2,2-dimethylbutyl)-n-(1h-pyrrolo[2,3-b]pyridin-4-yl)benzamide Chemical compound C1=CC(C(N)C(C)(C)CC)=CC=C1C(=O)NC1=CC=NC2=C1C=CN2 HVFBLNMGJWVBOH-UHFFFAOYSA-N 0.000 claims 1
- IZTDNPWBQHCWAF-UHFFFAOYSA-N 4-(1-amino-2,2-dimethylbutyl)-n-pyridin-4-ylbenzamide Chemical compound C1=CC(C(N)C(C)(C)CC)=CC=C1C(=O)NC1=CC=NC=C1 IZTDNPWBQHCWAF-UHFFFAOYSA-N 0.000 claims 1
- QRIIJGVRMJWJMC-UHFFFAOYSA-N 4-(1-amino-2,2-dimethylpropyl)-n-(1h-pyrrolo[2,3-b]pyridin-4-yl)benzamide Chemical compound C1=CC(C(N)C(C)(C)C)=CC=C1C(=O)NC1=CC=NC2=C1C=CN2 QRIIJGVRMJWJMC-UHFFFAOYSA-N 0.000 claims 1
- MFYXHARIDVVKQE-UHFFFAOYSA-N 4-(1-amino-2-methylpropyl)-n-pyridin-4-ylbenzamide Chemical compound C1=CC(C(N)C(C)C)=CC=C1C(=O)NC1=CC=NC=C1 MFYXHARIDVVKQE-UHFFFAOYSA-N 0.000 claims 1
- GUVVJWIZMJTOHB-UHFFFAOYSA-N 4-(1-amino-3,3-dimethylbutyl)-n-pyridin-4-ylbenzamide Chemical compound C1=CC(C(N)CC(C)(C)C)=CC=C1C(=O)NC1=CC=NC=C1 GUVVJWIZMJTOHB-UHFFFAOYSA-N 0.000 claims 1
- DMIYJAIUCNVDNZ-UHFFFAOYSA-N 4-(1-aminobutyl)-n-(1h-pyrrolo[2,3-b]pyridin-4-yl)benzamide Chemical compound C1=CC(C(N)CCC)=CC=C1C(=O)NC1=CC=NC2=C1C=CN2 DMIYJAIUCNVDNZ-UHFFFAOYSA-N 0.000 claims 1
- OXBJQHBEBMMYCJ-UHFFFAOYSA-N 4-(1-aminoethyl)-n-pyridin-4-ylnaphthalene-1-carboxamide Chemical compound C12=CC=CC=C2C(C(N)C)=CC=C1C(=O)NC1=CC=NC=C1 OXBJQHBEBMMYCJ-UHFFFAOYSA-N 0.000 claims 1
- AFPVZEOZNLCEFO-UHFFFAOYSA-N 4-(1-aminopentyl)-n-pyridin-4-ylbenzamide Chemical compound C1=CC(C(N)CCCC)=CC=C1C(=O)NC1=CC=NC=C1 AFPVZEOZNLCEFO-UHFFFAOYSA-N 0.000 claims 1
- ZZGFVFADCZZOTR-UHFFFAOYSA-N 4-(1-aminopropyl)-n-(1h-pyrrolo[2,3-b]pyridin-4-yl)benzamide Chemical compound C1=CC(C(N)CC)=CC=C1C(=O)NC1=CC=NC2=C1C=CN2 ZZGFVFADCZZOTR-UHFFFAOYSA-N 0.000 claims 1
- GQRHXVADWRNQSJ-UHFFFAOYSA-N 4-(1-aminopropyl)-n-pyridin-4-ylbenzamide Chemical compound C1=CC(C(N)CC)=CC=C1C(=O)NC1=CC=NC=C1 GQRHXVADWRNQSJ-UHFFFAOYSA-N 0.000 claims 1
- BEIPZGFAWMRBKW-UHFFFAOYSA-N 4-(aminomethyl)-n-pyridin-4-ylbenzamide Chemical compound C1=CC(CN)=CC=C1C(=O)NC1=CC=NC=C1 BEIPZGFAWMRBKW-UHFFFAOYSA-N 0.000 claims 1
- XQKMBMGZZKVNKI-UHFFFAOYSA-N 4-[(1-aminocyclohexa-2,4-dien-1-yl)methyl]-n-pyridin-4-ylbenzamide Chemical compound C=1C=C(C(=O)NC=2C=CN=CC=2)C=CC=1CC1(N)CC=CC=C1 XQKMBMGZZKVNKI-UHFFFAOYSA-N 0.000 claims 1
- RXVVCDYBIKNPMY-UHFFFAOYSA-N 4-[(1-aminocyclohexyl)methyl]-n-pyridin-4-ylbenzamide Chemical compound C=1C=C(C(=O)NC=2C=CN=CC=2)C=CC=1CC1(N)CCCCC1 RXVVCDYBIKNPMY-UHFFFAOYSA-N 0.000 claims 1
- UTWIBGAVMAMFLG-UHFFFAOYSA-N 4-[(1-aminocyclopentyl)methyl]-n-pyridin-4-ylbenzamide Chemical compound C=1C=C(C(=O)NC=2C=CN=CC=2)C=CC=1CC1(N)CCCC1 UTWIBGAVMAMFLG-UHFFFAOYSA-N 0.000 claims 1
- KVEPLQYOHUJLRM-UHFFFAOYSA-N 4-[2-(1-aminocyclobutyl)ethyl]-n-pyridin-4-ylbenzamide Chemical compound C=1C=C(C(=O)NC=2C=CN=CC=2)C=CC=1CCC1(N)CCC1 KVEPLQYOHUJLRM-UHFFFAOYSA-N 0.000 claims 1
- DYNBQBMJMRSQIS-UHFFFAOYSA-N 4-[2-(1-aminocyclopropyl)ethyl]-n-(1h-pyrrolo[2,3-b]pyridin-4-yl)benzamide Chemical compound C=1C=C(C(=O)NC=2C=3C=CNC=3N=CC=2)C=CC=1CCC1(N)CC1 DYNBQBMJMRSQIS-UHFFFAOYSA-N 0.000 claims 1
- OAGHQOGYIPJBMH-UHFFFAOYSA-N 4-[2-(1-aminocyclopropyl)ethyl]-n-pyridin-4-ylbenzamide Chemical compound C=1C=C(C(=O)NC=2C=CN=CC=2)C=CC=1CCC1(N)CC1 OAGHQOGYIPJBMH-UHFFFAOYSA-N 0.000 claims 1
- HBQICHDVACJWLN-UHFFFAOYSA-N 4-[amino-(4-methoxyphenyl)methyl]-n-pyridin-4-ylbenzamide Chemical compound C1=CC(OC)=CC=C1C(N)C1=CC=C(C(=O)NC=2C=CN=CC=2)C=C1 HBQICHDVACJWLN-UHFFFAOYSA-N 0.000 claims 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- NWUKZQQHKGVGHB-UHFFFAOYSA-N 5-amino-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid Chemical compound OC(=O)C1=CC=C2C(N)CCCC2=C1 NWUKZQQHKGVGHB-UHFFFAOYSA-N 0.000 claims 1
- SLRGZZIYYHTKSM-XYPYZODXSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)NC1=CC=NC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)NC1=CC=NC=C1 SLRGZZIYYHTKSM-XYPYZODXSA-N 0.000 claims 1
- 201000005948 Donohue syndrome Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010022491 Insulin resistant diabetes Diseases 0.000 claims 1
- 206010024604 Lipoatrophy Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000011032 Werner Syndrome Diseases 0.000 claims 1
- IYOZTVGMEWJPKR-IJLUTSLNSA-N Y-27632 Chemical compound C1C[C@@H]([C@H](N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-IJLUTSLNSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000015978 inherited metabolic disease Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 230000003212 lipotrophic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 0 CC1(*)C=NC=CC(C)=C1 Chemical compound CC1(*)C=NC=CC(C)=C1 0.000 description 5
- GPCQIJHZALEOMP-UHFFFAOYSA-N Cc1cc(CCC2N)c2cc1 Chemical compound Cc1cc(CCC2N)c2cc1 GPCQIJHZALEOMP-UHFFFAOYSA-N 0.000 description 1
- RVYMOWKHMXUHRS-UHFFFAOYSA-N Cc1ccc(C(CCC2)N)c2c1 Chemical compound Cc1ccc(C(CCC2)N)c2c1 RVYMOWKHMXUHRS-UHFFFAOYSA-N 0.000 description 1
- JQOUGGPGOWRLPX-UHFFFAOYSA-N Cc1ccc(CNCC2)c2c1 Chemical compound Cc1ccc(CNCC2)c2c1 JQOUGGPGOWRLPX-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54554504P | 2004-02-18 | 2004-02-18 | |
| GBGB0403635.6A GB0403635D0 (en) | 2004-02-18 | 2004-02-18 | Pyridinocarboxamides with improved activity as kinase inhibitors |
| PCT/IB2005/000600 WO2005082367A1 (en) | 2004-02-18 | 2005-02-18 | Kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007523155A JP2007523155A (ja) | 2007-08-16 |
| JP2007523155A5 true JP2007523155A5 (https=) | 2008-03-13 |
Family
ID=32039983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006553706A Pending JP2007523155A (ja) | 2004-02-18 | 2005-02-18 | キナーゼ阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070191420A1 (https=) |
| EP (1) | EP1715862A1 (https=) |
| JP (1) | JP2007523155A (https=) |
| GB (1) | GB0403635D0 (https=) |
| WO (1) | WO2005082367A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2550361C (en) | 2003-12-19 | 2014-04-29 | Prabha Ibrahim | Compounds and methods for development of ret modulators |
| US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
| US20080207677A1 (en) * | 2004-12-31 | 2008-08-28 | Gpc Biotech Ag | Napthyridine Compounds As Rock Inhibitors |
| US7737279B2 (en) | 2005-05-10 | 2010-06-15 | Bristol-Myers Squibb Company | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same |
| AU2006272951A1 (en) | 2005-05-17 | 2007-02-01 | Plexxikon, Inc. | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
| CN102206216B (zh) | 2005-06-22 | 2014-11-12 | 普莱希科公司 | 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物 |
| JP2009505948A (ja) * | 2005-07-11 | 2009-02-12 | デブジェン エヌブイ | キナーゼ阻害剤としてのアミド誘導体 |
| US8211919B2 (en) | 2005-09-02 | 2012-07-03 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
| US7741290B2 (en) | 2006-06-01 | 2010-06-22 | The Board of Trustee of The Leland Stanford Juinior University | Method of preventing progression of hypertension-induced heart failure with PKC peptides |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
| AU2007336811A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| AR067354A1 (es) * | 2007-06-29 | 2009-10-07 | Sunesis Pharmaceuticals Inc | Compuestos utiles como inhibidores de la raf quinasa |
| JP2010533729A (ja) | 2007-07-17 | 2010-10-28 | プレキシコン，インコーポレーテッド | キナーゼ調節のための化合物と方法、及びそのための適応 |
| KR20100103830A (ko) * | 2008-01-21 | 2010-09-28 | 가부시키가이샤 시세이도 | Ⅴｅｇｆｃ 생성 촉진제 |
| HRP20170357T1 (hr) * | 2008-10-10 | 2017-05-05 | Vm Discovery, Inc. | Sastavi i postupci za liječenje poremećaja zbog konzumacije alkohola, bolova i ostalih bolesti |
| KR101739994B1 (ko) | 2009-04-03 | 2017-05-25 | 에프. 호프만-라 로슈 아게 | 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도 |
| AR077033A1 (es) * | 2009-06-11 | 2011-07-27 | Hoffmann La Roche | Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| GB0914726D0 (en) * | 2009-08-24 | 2009-09-30 | Univ Manchester | Kinase inhibitors |
| NZ599866A (en) | 2009-11-06 | 2014-09-26 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| EP2523957A1 (en) | 2010-01-12 | 2012-11-21 | F. Hoffmann-La Roche AG | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| US8785648B1 (en) | 2010-08-10 | 2014-07-22 | The Regents Of The University Of California | PKC-epsilon inhibitors |
| KR101911972B1 (ko) | 2011-02-07 | 2018-10-25 | 플렉시콘 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
| TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| EP2714688B1 (en) | 2011-05-26 | 2016-02-24 | Daiichi Sankyo Company, Limited | Heterocyclic compounds as protein kinase inhibitors |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| US20170114323A1 (en) * | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| EP3180003B1 (en) | 2014-07-01 | 2022-01-12 | The Regents of the University of California | Pkc-epsilon inhibitors |
| WO2017023684A2 (en) * | 2015-07-31 | 2017-02-09 | Progenra, Inc. | Covalent irreversible inhibitors of usp7 as anti-cancer agents |
| EP4088719A1 (en) | 2015-10-13 | 2022-11-16 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
| WO2017064119A1 (en) | 2015-10-13 | 2017-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
| KR101844984B1 (ko) * | 2016-05-31 | 2018-04-03 | 한림대학교 산학협력단 | 5원 헤테로사이클릭 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
| US11273154B2 (en) | 2017-03-03 | 2022-03-15 | Progenra, Inc. | Azole compounds as ubiquitin-specific protease USP7 inhibitors |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| SMT202500271T1 (it) | 2020-07-02 | 2025-09-12 | Incyte Corp | Composti di urea triciclici come inibitori di v617f di jak2 |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
| CN119173514A (zh) | 2022-03-17 | 2024-12-20 | 因赛特公司 | 作为jak2 v617f抑制剂的三环脲化合物 |
| WO2024071371A1 (ja) * | 2022-09-30 | 2024-04-04 | ユビエンス株式会社 | 複素環式化合物 |
| WO2025224050A1 (en) | 2024-04-22 | 2025-10-30 | Institut National de la Santé et de la Recherche Médicale | Methods of treatment of patients suffering from hypomelanosis of ito |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005723A1 (fr) * | 1988-11-24 | 1990-05-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Composes de trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane et leur utilisation en medecine |
| DK0641781T3 (da) * | 1991-09-06 | 2000-09-18 | Yoshitomi Pharmaceutical | 4-Amino(alkyl)cyclohexan-1-carboxamidforbindelser og anvendelse af disse |
| EP1195372A1 (en) * | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
| JP2003073357A (ja) * | 2001-09-03 | 2003-03-12 | Mitsubishi Pharma Corp | アミド化合物を含有するＲｈｏキナーゼ阻害剤 |
| GB0206861D0 (en) * | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Medicaments |
| JP2007514003A (ja) * | 2003-12-15 | 2007-05-31 | アルミラル プロデスファルマ アーゲー | アデノシン受容体アンタゴニストとしての２，６−ビスヘテロアリール−４−アミノピリミジン |
| US7618964B2 (en) * | 2004-12-23 | 2009-11-17 | Hoffmann-La Roche Inc. | Benzamide derivatives, their manufacture and use as pharmaceutical agents |
-
2004
- 2004-02-18 GB GBGB0403635.6A patent/GB0403635D0/en not_active Ceased
-
2005
- 2005-02-18 EP EP05708700A patent/EP1715862A1/en not_active Withdrawn
- 2005-02-18 US US10/589,875 patent/US20070191420A1/en not_active Abandoned
- 2005-02-18 WO PCT/IB2005/000600 patent/WO2005082367A1/en not_active Ceased
- 2005-02-18 JP JP2006553706A patent/JP2007523155A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007523155A5 (https=) | ||
| RU2470011C2 (ru) | Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов | |
| TWI376370B (en) | Compounds for inflammation and immune-related uses | |
| JP2008513515A5 (https=) | ||
| JP2009531280A5 (https=) | ||
| CN1474818A (zh) | 含有稠合杂环化合物或其盐的糖尿病预防或治疗药 | |
| TW200819122A (en) | Chemical compounds | |
| JP2009537559A5 (https=) | ||
| JP2015523339A5 (https=) | ||
| CA2513092A1 (en) | Compounds for the treatment of metabolic disorders | |
| CN103097353A (zh) | 新型免疫调节剂和抗炎化合物 | |
| JP2011504903A5 (https=) | ||
| JP2020502111A5 (https=) | ||
| JP2017505293A5 (https=) | ||
| CA2521621A1 (en) | Compounds for the treatment of metabolic disorders | |
| CN103102348B (zh) | 噁二唑类化合物及其制备方法、药物组合物及其用途 | |
| JP2007500145A5 (https=) | ||
| JP2010522710A5 (https=) | ||
| JP2015519322A5 (https=) | ||
| CN104640544A (zh) | 血脂异常症治疗剂 | |
| CA2522738A1 (en) | Compounds for the treatment of metabolic disorders | |
| JP2019520344A5 (https=) | ||
| CA2521589A1 (en) | Compounds for the treatment of metabolic disorders | |
| JP2020534266A5 (https=) | ||
| JP2005532397A5 (https=) |